A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Clinical trial NCT05845814 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05845814
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-23
- Primary completion
- 2027-05-31
- Enrollment
- 390
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.